AIBIOS

About:

AIBIOS is a drug discovery and R&D biotech company with bioinformatics intelligence focusing on immune diseases.

Top Investors: SBI Investment

Description:

AIBIOS has designed and developed a series of novel small molecules which modulate both the innate (macrophages) and adaptive immune system to treat therapeutic indications of Gastroenterology, Respiratory, and Neurological diseases.

Total Funding Amount:

850M JPY

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Irvine, California, United States

Founded Date:

2018-02-12

Contact Email:

info(AT)aibios.com

Founders:

Akio Sato

Number of Employees:

1-10

Last Funding Date:

2021-04-28

IPO Status:

Private

Industries: